case_images: PMC10404849_01
case_images: Progressing skin lesions on day 5 of hospitalization.
case_images: fmed-10-1210026-g0001.jpg
case_images: PMC10404849_01_fmed-10-1210026-g0001.jpg
case_images: F1
case_images: The spectrum of new complaints included nasal pain and hemorrhagic crusts on the red border of the lips (Figure 1).
case_images: Skin process dynamics. (A) On the day of etanercept administration, palmar surfaces featured multiple bullae filled with serous content followed by erosive defects. (B) On day 11, previously erosive surfaces were epithelialized, and residual desquamation and depigmentation were present in the previously affected areas.
case_images: fmed-10-1210026-g0002.jpg
case_images: PMC10404849_01_fmed-10-1210026-g0002.jpg
case_images: F2
case_images: Positive dynamics of the skin process were also observed (Figures 2-4).
case_images: Skin process dynamics. (A) On the day of etanercept administration, multiple erosive areas with confluent erythematous rashes on the back were observed. (B) On day 11, we observed epithelialized previously erosive areas and foci of depigmentation in previously affected areas.
case_images: fmed-10-1210026-g0003.jpg
case_images: PMC10404849_01_fmed-10-1210026-g0003.jpg
case_images: F3
case_images: Positive dynamics of the skin process were also observed (Figures 2-4).
case_images: Skin process dynamics. (A) On the day of etanercept administration, the facial area with maculopapular rashes prone to confluence and hemorrhagic rashes were visible on the skin in the area of the red border of the lips. (B) On day 11, the facial area with foci of depigmentation and mucous membranes without signs of a pathological process were observed.
case_images: fmed-10-1210026-g0004.jpg
case_images: PMC10404849_01_fmed-10-1210026-g0004.jpg
case_images: F4
case_images: Positive dynamics of the skin process were also observed (Figures 2-4).